血浆神经元来源细胞外囊泡生物标志物与阿尔茨海默病的关联:巴尔的摩老龄化纵向研究
该病例对照研究基于巴尔的摩老龄化纵向研究(BLSA)队列,分析了128例未来发展为阿尔茨海默病(AD)的参与者和222名年龄性别匹配的认知正常对照的887份纵向血浆样本,发现神经元富集细胞外囊泡(nEV)中p-tau181、p-tau231、pSer312-IRS-1、pY-IRS-1及nEV直径在AD临床前阶段已升高,联合模型在训练集预测AD的AUC为89.6%,并在测试集验证(AUC 80%)。
要点
- 临床前AD患者血浆nEV中p-tau181、p-tau231、pSer312-IRS-1、pY-IRS-1及nEV直径纵向升高。
- 联合临床前纵向数据的模型预测AD训练集AUC 89.6%,测试集AUC 80%。
- nEV生物标志物临床前水平与认知表现相关,支持其作为AD血检候选。
核心结论
- 研究验证了nEV生物标志物候选物,并证明其临床前纵向轨迹可预测AD诊断。
研究设计与样本
- 病例对照研究,纳入BLSA队列128例未来AD患者和222名年龄性别匹配认知正常对照的887份纵向血浆样本。
- 另分析约翰霍普金斯AD研究中心64例临床AD患者和对照的128份重复样本。
- 数据收集于2016年9月至2018年1月,分析于2019年3月进行。
主要发现
- 未来AD患者较对照有更高的p-tau181、p-tau231、pSer312-IRS-1、pY-IRS-1和nEV直径,而Aβ42、总tau、TSG101和nEV浓度相似。
- BLSA训练集联合模型预测AD的AUC为89.6%,敏感性81.8%,特异性85.8%。
- BLSA测试集验证AUC为80%,敏感性55.6%,特异性88.7%。
- JHADRC队列训练集鉴别AD的AUC为98.9%,敏感性100%,特异性94.7%;测试集AUC为76.7%,敏感性91.7%,特异性60%。
- 临床前nEV生物标志物水平与认知表现相关。
临床怎么用
- nEV生物标志物组合有望作为AD临床前阶段的血液检测工具,用于试验入组和早期诊断。
- 临床前纵向轨迹比单时间点检测可能提供更强的AD预测价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Blood biomarkers able to diagnose Alzheimer disease (AD) at the preclinical stage would enable trial enrollment when the disease is potentially reversible. Plasma neuronal-enriched extracellular vesicles (nEVs) of patients with AD were reported to exhibit elevated levels of phosphorylated (p) tau, Aβ42, and phosphorylated insulin receptor substrate 1 (IRS-1). OBJECTIVE: To validate nEV biomarkers as AD predictors. DESIGN, SETTING, PARTICIPANTS: This case-control study included longitudinal plasma samples from cognitively normal participants in the Baltimore Longitudinal Study of Aging (BLSA) cohort who developed AD up to January 2015 and age- and sex-matched controls who remained cognitively normal over a similar length of follow-up. Repeated samples were blindly analyzed over 1 year from participants with clinical AD and controls from the Johns Hopkins Alzheimer Disease Research Center (JHADRC). Data were collected from September 2016 to January 2018. Analyses were conducted in March 2019. MAIN OUTCOMES AND MEASURES: Neuronal-enriched extracellular vesicles were immunoprecipitated; tau, Aβ42, and IRS-1 biomarkers were quantified by immunoassays; and nEV concentration and diameter were determined by nanoparticle tracking analysis. Levels and longitudinal trajectories of nEV biomarkers between participants with future AD and control participants were compared. RESULTS: Overall, 887 longitudinal plasma samples from 128 BLSA participants who eventually developed AD and 222 age and sex-matched controls who remained cognitively normal were analyzed. Participants were followed up (from earliest sample to AD symptom onset) for a mean (SD) of 3.5 (2.31) years (range, 0-9.73 years). Overall, 161 participants were included in the training set, and 80 were in the test set. Participants in the BLSA cohort with future AD (mean [SD] age, 79.09 [7.02] years; 68 women [53.13%]) had longitudinally higher p-tau181, p-tau231, pSer312-IRS-1, pY-IRS-1, and nEV diameter than controls (mean [SD] age, 76.2 [7.36] years; 110 women [50.45%]) but had similar Aβ42, total tau, TSG101, and nEV concentration. In the training BLSA set, a model combining preclinical longitudinal data achieved 89.6% area under curve (AUC), 81.8% sensitivity, and 85.8% specificity for predicting AD. The model was validated in the test BLSA set (80% AUC, 55.6% sensitivity, 88.7% specificity). Preclinical levels of nEV biomarkers were associated with cognitive performance. In addition, 128 repeated samples over 1 year from 64 JHADRC participants with clinical AD and controls were analyzed. In the JHADRC cohort (35 participants with AD: mean [SD] age, 74.03 [8.73] years; 18 women [51.43%] and 29 controls: mean [SD] age, 72.14 [7.86] years; 23 women [79.31%]), nEV biomarkers achieved discrimination with 98.9% AUC, 100% sensitivity, and 94.7% specificity in the training set and 76.7% AUC, 91.7% sensitivity, and 60% specificity in the test set. CONCLUSIONS AND RELEVANCE: We validated nEV biomarker candidates and further demonstrated that their preclinical longitudinal trajectories can predict AD diagnosis. These findings motivate further development of nEV biomarkers toward a clinical blood test for AD.
引用
- Kapogiannis D, Mustapic M, Shardell MD, et al. Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2019. PMID: 31305918. doi:10.1001/jamaneurol.2019.2462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。